Drug intelligence / Profile preview

PP6c siRNA

Development stage
Preclinical
Lead developer
Shanghai Jiao Tong University
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intravenous
01

Overview

PP6c siRNA is a small interfering RNA (siRNA) designed to silence the expression of the catalytic subunit of protein phosphatase 6 (PP6c, encoded by the PPP6C gene). PP6 is a serine/threonine protein phosphatase that plays a critical role in the DNA damage response by regulating the activation of DNA-dependent protein kinase (DNA-PK). Research, including studies from Shanghai Jiao Tong University, has demonstrated that PP6c is overexpressed in glioblastoma (GBM) and correlates with poor patient survival and radioresistance. By knocking down PP6c, this siRNA inhibits DNA-PK activation and reduces the DNA-repair capacity of tumor cells, thereby sensitizing them to radiotherapy. In preclinical xenograft models, PP6c knockdown has been shown to increase radiosensitivity and prolong survival, positioning it as a potential therapeutic strategy for enhancing the efficacy of radiation in aggressive cancers.

Other names
siRNA targeting PP6csiRNA targeting PPP6CProtein phosphatase 6 catalytic subunit siRNA
02

Targets

PPP6C (PP6 / PPP6C)

Beyond the preview

Go deeper on PP6c siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PP6c siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call